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RESULTS: A total of 54,341 RA patients met the study inclusion criteria; mean 
age 59 years, 67% female. Of these patients, a total of 1033 (1.9%) died in 2011. 
Age and sex-specific mortality rates were: male/age 18-35 (0/532;0.0%); 
female/age 18-35 (1/2391;0.0%%); male/age 36-55 (16/4889 0.3%); female/age 36-55 
(27/13462;0.2%); male/age 56-75 (191/9455;2.0%); female/age 56-75 
(190/15891;1.2%); male/age 76+ (271/3128;8.5%); female/age 76+ (337/4593;7.3%). 
CONCLUSIONS: This is the first study to describe annual mortality in a large 
prevalence-based sample of U.S. RA patients. Additional analyses to examine 
risk factors and suspected causes of mortality are warranted.  
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EVIDENCE ON SAFETY OF METAL-ON-METAL HIP RESURFACING 
ARTHROPLASTY  
Sehatzadeh S, Levin L 
Health Quality Ontario, Toronto, ON, Canada  
OBJECTIVES: Metal-on-metal hip resurfacing arthroplasty (MOM HRA) is an 
alternative to total hip arthroplasty in young patients. There are multiple reports 
indicating higher rate of revision for MOM HRA and health regulators are 
currently scrutinizing failure rates and safety of these implants. The revision 
rates of implants licensed in Canada were compared with the benchmark set by 
the National Institute of Clinical Excellence (NICE), i.e., a revision rate of 10% or 
less at 10 years. METHODS: Studies published from January 1, 2009 to February 
13, 2012 were included. The literature was examined to identify articles 
discussing the biological effects of metal implants. RESULTS: The revision rates 
for MOM HRA with BHR, ConservePlus, and Cormet implants met NICE criteria. 
Revision rate for ReCap implant was 2% at a mean follow-up of 2.9 years. Two 
studies reported revision rates of 3.7% and 11% for Durum implant at a mean 
follow-up of 5 years. The ASR implant had a revision rate of 10.9% at 5 years. In 
addition to implant design, several factors including selection of patients and 
skills of the surgeons in proper positioning of the implant that helps to reduce 
rate of wear contributed to the success of the procedure. The consensus among 
orthopedic surgeons is that the ideal patients for MOM HRA are young male 
patients with end-stage hip osteoarthritis, good bone quality, and proper 
anatomy around the affected joint. There are reports of high levels of metal ions 
in the blood and urine of patients with these implants. Production of metal 
debris due to friction between the 2 components may result in inflammation in 
the joint or development of a soft tissue mass leading to implant failure. 
CONCLUSIONS: MOM HRA can be beneficial for appropriately selected patients, 
provided the surgeon has the surgical skills required for performing this 
procedure.  
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BUDGET IMPACT ANALYSIS OF OSTEOPOROSIS DRUG THERAPY 
REIMBURSEMENT CRITERIA UPDATES IN KOREA  
Park SY1, Kim Y2, Hyun MK2, Park JY2, Ahn J2 
1SKKU, Suwon, South Korea, 2National Evidence-based Healthcare Collaborating Agency (NECA), 
Seoul, South Korea  
Prior to 2012, the reimbursement criteria for osteoporosis medications has been 
criticized for its strict BMD indication and 6-month coverage period in Korea. The 
cost estimate of expanding coverage to clinically recommended level was 130 
billion KRW. OBJECTIVES: To suggest a better estimate of budget impacts for 
osteoporosis drug therapy in Korea METHODS: A 5-year semi-annual Markov 
model focusing on the fracture-preventing effects of osteoporosis medications 
was constructed. Fracture-preventing effects of osteoporosis drugs were 
extracted from previous systematic reviews and the HIRA’s national health 
insurance claims database from 2006 to 2008 was used to estimate the 
probabilities and costs for modeling. Mortality rate at each stage was estimated 
from the literature and the Statistics Korea. The Korean National Health and 
Nutrition Examination Survey data and Korean FRAX tool were utilized to 
calculate the population at each stage. The scenarios of reimbursement criteria 
expansion were composed of BMD T-score, coverage period, and including high-
fracture-risk patients with osteopenia. RESULTS: Reimbursement coverage 
expansion is expected to increase budget input, but the increase gradually 
decrease over time. If the reimbursement criteria is expanded to T-score≤-2.5, 
coverage period increased to 1 year, but excluding high-fracture-risk osteopenia, 
then about 450 billion KRW is required for osteoporosis drug acquisition for 5 
years along with 120 billion KRW saving for fracture treatment costs compared to 
the existing criteria. Considering both expansion costs and fracture costs, the 
reduction in fracture costs partially offsets the expanded coverage of 
osteoporosis drugs. In summary, 87 billion KRW was estimated for the first year 
budget impact and it gradually decreases to about 50 billion KRW in the fifth 
year. CONCLUSIONS: This budget impact analysis considering both increase in 
osteoporosis drug cost and saved fracture cost shows the total health insurance 
budget impact is lower than the previously suggested amount.  
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COST PER TREATED PATIENT FOR BIOLOGICS IN RHEUMATOID ARTHRITIS, 
PSORIATIC ARTHRITIS, PSORIASIS AND ANKYLOSING SPONDYLITIS USING 
CLAIMS DATA  
Bonafede MM1, Joseph G2, Princic N1, Harrison DJ2 
1Truven Health Analytics, Cambridge, MA, USA, 2Amgen, Inc., Thousand Oaks, CA, USA  
OBJECTIVES: To estimate annual cost per treated patient for etanercept, 
adalimumab, infliximab, abatacept, rituximab, golimumab, certolizumab, and 
ustekinumab in rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, and 
ankylosing spondylitis in a US claims population. METHODS: MarketScan 
Commercial Database was used to identify patients (18-63 years) with ≥1 claim 
for a biologic of interest between January 1, 2008 and December 31, 2010 
preceded by ≥6-months of enrollment and a diagnosis of RA, psoriasis, psoriatic 
arthritis, or ankylosing spondylitis. The first drug claim meeting these criteria 
defined the index date and biologic. “Continuing” patients had ≥1 claim for the 
same biologic before their index date, “New” patients did not. Patients were 
required to be continuously enrolled for 1-year following the index claim. 
Patients with Crohn’s disease, or ulcerative colitis pre-index were excluded since 
not all biologics are approved for these indications. Mean monthly dose and total 
dose of other biologics after discontinuation of their index biologic was 
calculated for the 12-months after index. Wholesale acquisition costs and the 
Medicare Physician Fee Schedule were applied to the mean monthly dose and 
related drug administration to calculate cost per treated patient. RESULTS: A 
total of 69,349 patients were included, 92.3% received etanercept (32,298), 
adalimumab (20,582), or infliximab (11,157). Patient characteristics were similar 
across groups; mean age 47.8 years (SD 10.2), 63% female. Mean annual cost per 
treated patient pooled across indications was $20,508 etanercept, $21,179 
adalimumab, and $23,446 infliximab. Cost per treated patient in RA (55% of 
patients) ranged from $18,888 abatacept to $22,158 infliximab and in psoriasis, 
(20% of patients), from $21,034 adalimumab to $31,478 ustekinumab. 
CONCLUSIONS: Based on drug utilization from this US managed care population, 
of agents approved for all indications, etanercept had the lowest cost per treated 
patient across all indications. In RA, abatacept had the lowest cost, whereas 
infliximab had the highest.  
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COST PER TREATED PATIENT FOR BIOLOGICS ACROSS ADULT INDICATIONS 
USING CLAIMS DATA  
Schabert VF1, Korn J2, Bilir P3, DeKoven M1, Harrison DJ4, Joseph G4 
1IMS Health Consulting Group, Alexandria, VA, USA, 2IMS Health, Waltham, MA, USA, 3IMS 
Health Consulting Group, Redwood City, CA, USA, 4Amgen, Inc., Thousand Oaks, CA, USA  
OBJECTIVES: To estimate annual biologic cost per treated patient in rheumatoid 
arthritis (RA), plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis 
using drug utilization from US managed care. METHODS: The IMS LifeLink 
Health Plan Claims Database was used to identify adults (18-63 years) with a 
claim for etanercept, adalimumab, infliximab, abatacept, rituximab, golimumab, 
certolizumab, or ustekinumab between January 1, 2008 and December 31, 2010 
preceded by ≥180-days of enrollment. Patients had to have a qualifying diagnosis 
between 180 days before and 30 days after index and be enrolled for ≥360 days 
post-index. The first biologic claim meeting these criteria defined the index date. 
Patients with pre-index Crohn’s disease, ulcerative colitis, non-Hodgkins 
lymphoma, or chronic lymphocytic lymphoma were excluded. Annual cost per 
treated patient equaled total dose for the index biologic and biologics taken after 
discontinuation of the index biologic multiplied by October 2012 WAC, plus 
number of administrations multiplied by the 2012 Medicare Physician Fee 
Schedule costs. RESULTS: Of 35,525 included patients; 92.7% received etanercept 
(n=16,704), adalimumab (n=10,154), or infliximab (n=6,056). Most patients (63%) 
were female, mean age 48.9 years and treated for RA (56%). Pooled across 
indications, cost per treated patient for agents approved for all indications was 
$20,284 for etanercept, $20,010 for adalimumab, and $22,795 for infliximab. Cost 
per treated patient in RA was $19,251 for etanercept, $20,387 for adalimumab, 
$21,585 for infliximab. The range in other agents was from $16,286 for 
golimumab (n=120) to $19,710 for certolizumab (n=101). In psoriasis, cost per 
treated patient ranged from $20,261 for adalimumab (n=1,874), to $34,951for 
ustekinumab (n=116). The costs in other groups were similar to those in RA. 
CONCLUSIONS: Of agents approved for all indications, infliximab, which is 
infused, had higher costs than adalimumab or etanercept which are self-
injected. Although some new agents had lower costs in RA, sample size for these 
agents was limited.  
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INPATIENT HOSPITAL COSTS AND LENGTH OF STAY FOR THE TREATMENT OF 
OSTEOPOROSIS FRACTURES IN CHINA  
Li J1, Burge RT2, Ye WW3, Yang Y4, Du F5, Ma Y1, Zhang J1 
1China Health Insurance Research Association, Beijing, China, 2Eli Lilly and Company, 
Indianapolis, IN, USA, 3Lilly Suzhou Pharmaceutical Co., Ltd. Shanghai Branch, Shanghai, China, 
4Eli Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, China, 5Beijing Brainpower 
Pharma Consulting Co. Ltd., Beijing, China  
OBJECTIVES: The prevalence of osteoporosis fractures is anticipated to increase 
rapidly due to China's aging population. However, nationally representative data 
on inpatient hospital costs and length of stay (LOS) for osteoporosis fractures are 
lacking. The study was to estimate hospitalization costs, LOS, costs/day, and the 
co-pay burden among patients with osteoporosis fractures in China. METHODS: 
Data were extracted from the China Health Insurance Research Association 
claim database which includes a nationwide, cross-sectional sampling of 
inpatients from 2008-2010. The descriptive analysis included inpatients (≥50 
years) who had discharge diagnosis of fracture (vertebral, hip, non-
vertebral/non-hip(NVNH), or multiple fractures) and either had a diagnosis of 
pathological osteoporosis or osteoporosis drug treatment. Total medical costs 
and LOS were calculated and compared by Wilcoxon test within subgroups. 
RESULTS: The analysis included 830 patients (female:77.4%, mean age:73.4 
years). The medians of overall LOS and total costs were 19 days and 18587.0 RMB. 
Patients≥70 years (n=581) had greater LOS and costs than patients <70 years 
(median: 19 vs. 17 days, p<0.01; 21527.6 vs. 14748.6 RMB, p<0.01). Cost/day in 2008 
was 801.9±861.9 RMB, which increased by 74.3% in 2009 and 89.2% in 2010. Hip 
fractures had the longest LOS (22 days) and highest cost (32593.8 RMB); and were 
significantly greater than NVNH fracture (18 days, p<0.01; 17185.0 RMB, p<0.01). 
Reimbursement of costs by basic health insurance in 2008, 2009 and 2010 was 
51.8%, 54.7%, and 60.8%, respectively; while the corresponding patient co-pay 
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burden was 48.2%, 45.3% and 39.2%. CONCLUSIONS: The study suggests the 
economic burden of osteoporosis fractures is substantial in terms of LOS and 
inpatient costs and elderly fracture patients consume significantly more 
resources. Patient co-pay rates decreased due to an increase in the 
reimbursement rates from health care. The rising trend in osteoporosis fractures 
may pose a huge burden to China.  
 
PMS20  
ADVERSE EVENTS COSTS ASSOCIATED WITH PAIN MANAGEMENT IN ADULT 
PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS IN FIVE 
LATIN AMERICAN COUNTRIES  
Mould-Quevedo J1, Luna-Casas G2, Garcia-Mollinedo L2, Rosado-Buzzo A2 
1Pfizer, Inc., New York, NY, USA, 2Links & Links S.A, de C.V., Mexico City, Mexico  
OBJECTIVES: Rheumatoid arthritis (RA), an autoimmune condition, and 
osteoarthritis (OA), a degenerative joint disorder, are both associated with 
inflammatory reactions. Pain relievers could ameliorate this economic burden; 
however depending on the first-line treatment chosen they could raise the 
likelihood of gastrointestinal (GI) complications or cardiovascular (CV) events. 
The aim of this study is to calculate the direct and indirect costs of GI and CV 
events associated with common pain relievers for RA and OA patients in Brazil, 
Mexico, Colombia, Argentina and Costa Rica from the public payer’s perspective. 
METHODS: Resource use and medical cost data was collected in 2011 from local 
official databases and public hospital records from each noted LA market (all 
costs are expressed in 2012 US$). Events considered in this assessment were: 
dyspepsia, symptomatic ulcer, major bleedings (severe GI complication), 
myocardial infarction, ischemic stroke and heart failure. Direct medical costs 
considered were: outpatient visits, inpatient costs, lab and diagnostic tests, 
acquisition drug costs, concomitant medication, and emergency room services. 
To estimate indirect costs, human capital approach was considered involving 
productivity losses based in average wages for each LA market. RESULTS: Among 
LA countries, Brazil showed the highest overall adverse event cost per patient 
with dyspepsia (US$97.10) and Costa Rica the lowest (US$57.00). In addition, a 
symptomatic ulcer cost ranged between US$933.00 - US$705.60; major bleeding 
(US$6,807.30 - US$4,960.40); myocardial infarction (US$13,330.30 - US$7916.70); 
ischemic stroke (US$6,427.20 - US$3125.00) and heart failure (US$7,221.70 - 
US$4,152.80). In average, Brazilian and Mexican overall costs were among the 
highest, as opposed to Argentina and Costa Rica which were among the 
countries with lowest costs. Indirect costs followed the same trend (less than 
15% of total direct costs). CONCLUSIONS: Unexpected event costs associated 
with pain relievers could raise the economic burden of OA and RA significantly 
in LA. Thus, these findings could help decision makers to identify cost-effective 
pain therapies in markets where this cost data is unavailable.  
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ECONOMIC OUTCOMES FOR CELECOXIB IN LATIN AMERICA: A COST-
EFFECTIVENESS STUDY OF COX-2 INHIBITORS AGAINST NSAIDS+PPI FOR 
ADULT PATIENTS WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS IN 
BRAZIL, MEXICO, COLOMBIA, ARGENTINA AND COSTA RICA  
Mould-Quevedo J 
Pfizer, Inc., New York, NY, USA  
OBJECTIVES: Osteoarthritis (OA) and rheumatoid arthritis (RA) are conditions 
that are associated with significant clinical burden and impact patients’ 
functional status and quality of life. Medical costs related to treating these 
common and disabling conditions place an economic strain on health care 
systems. The aim of this assessment is to compare celecoxib against 
nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) plus proton 
pump inhibitors (PPI) in five Latin American markets from the public payer’s 
perspective. METHODS: A cost-effectiveness evaluation was performed using a 
Markov modeling approach within a five-year time horizon (twelve-week cycles). 
The model compares celecoxib (200mg bid) against nsNSAIDs (naproxen 
500mg/bid; diclofenac 100mg/bid) alone and combined with PPI (omeprazole 
20mg/day). Model results were subdivided into two risk subpopulations: a) 
patients at low risk of GI and CV events (age 55+ with no prior risk factors); b) 
patients at high risk (age 65+ with previous risk factors). Efficacy and safety were 
retrieved from clinical literature (CONDOR Trial) and model uses Quality-
Adjusted Life Years Gained (QALYs) as effectiveness measurement. Resource use 
and medical cost data was collected from local official databases and public 
hospital records from each LA market (expressed in 2012 US$). Costs and 
consequences were discounted at 5% annually and probabilistic sensitivity 
analyses (PSA) were conducted. RESULTS: Celecoxib showed the highest health 
benefits (4.488 QALYs) compared to diclofenac (4.308 QALYs, +PPI 4.392 QALYs) 
and naproxen (4.241 QALYs, +PPI 4.355 QALYs). Regarding medical costs, in Brazil 
and Mexico celecoxib showed to be a cost-saving strategy within the high risk 
subpopulation. In other LA markets, celecoxib resulted as a cost-effective option 
with an average ICER of US$11,239.50 and US$8,046.20 in low and high risk 
subpopulations, respectively. PSA support robustness of the results. 
CONCLUSIONS: Despite higher acquisition cost compared to nsNSAIDs, celecoxib 
was found to be a cost-effective therapy for patients with OA and RA in multiple 
LA health care systems.  
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ECONOMIC BURDEN OF OSTEOPOROTIC FRACTURE IN ELDERLY IN SOUTH 
KOREA  
KIm J1, Lee TJ1, Lee E1, Jo S2, Kim S1, Park E3 
1Seoul National University, Seoul, South Korea, 2Health Insurance Review & Assessment Service, 
Seoul, South Korea, 3Inje University, Busan, South Korea  
OBJECTIVES: Osteoporotic Fractures (OF) in elderly people are common 
worldwide, and the predicted aging of populations is increasing the burden of OF 
on health care systems. This study estimates the economic burden of OF in aged 
65 years and over in South Korea from a societal perspective. METHODS: 
National health insurance claim databases were used to analyze annual health 
care utilization and medical costs of OF in the South Korean population (49.78 
million). We identified medical claims records for elderly people with a diagnosis 
of OF and estimated the costs by a macro-costing method from 2007 to 2011. 
RESULTS: From 2007 to 2011, there were 244,798 elderly patients with at least 1 
medical insurance claim related to OF. Most patients had a single fracture (83%), 
while 17% of all patients had two or more. By fracture site, vertebral fracture 
accounted for 76.3% of all fractures, followed by 9.9% for hip fracture and 7.5% 
for wrist fracture. The societal cost of OF increased annually, from $83.7 million 
in 2007 to $141.4 million in 2011. For the societal cost of OF, direct medical cost 
was $134.9 million in 2011, which includes cost of treatment ($88.3 million) and 
long-term care ($46.6 million). The direct non-medical cost (transportation and 
caregiver costs) was estimated at $6.5 million in 2011. Costs associated with 
morbidity and mortality of OF were excluded due to the characteristics of the 
patients such as age, disability level and age at death. CONCLUSIONS: The 
results of this study indicate that the economic burden associated with OF in 
elderly people in Korea is considerable and is expected to rise with the predicted 
increases in life expectancy and the number of elderly in South Korea. Therefore, 
effective management of the disease is necessary to reduce the growth in the 
economic burden of OF.  
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DRUG USE AND COST EVALUATION IN RHEUMATOID ARTHRITIS PATIENTS  
Adami S1, Bernardi D2, Rossi E3, Rossini M1, De Rosa M3 
1Rheumatology Unit, Dpt Medicine, University of Verona, Verona, Italy, 2CINECA, Casalecchio di 
Reno - Bologna, Italy, 3CINECA Interuniversity Consortium, Casalecchio di Reno , BO, Italy  
OBJECTIVES: To describe drug use, drug switch and cost evaluation in patients 
with rheumatoid arthritis (RA). METHODS: Data derived from ARNO Observatory, 
an Italian population-based patient-centric system through record linkage of 11 
million inhabitants. In a sub-cohort of 5,821,337 people, we identified 15,082 
subjects with rheumatoid arthritis in 2011. Data were retrived for all these 
patients back to 2010 in order to esteem disease incidence. A cohort matched by 
sex, age and local health unit was computed to estimate differences in health 
costs. RESULTS: Prevalence of RA was 0.26% with an average age of 62 years and 
a percentage of women of 77%. Incidence is about 0.03% per year. The cost per-
person is €2,823 per year, 128% more in comparison with pair-matched group. 
This cost is for €1,230 due to drugs (€564 specific drugs, €666 others), €1,024 due 
to hospitalization and €569 due to lab tests and diagnostic examinations. Most 
common drugs are methylprednisolone+prednisone (63% treated), methotrexate 
(47.2%) and hydroxychloroquine (31.6%). Biological drugs are used by 3% of 
patients, but this percentage is increasing by years. Patients treated with 
biological drugs cost three times higher than others. Patients usually start first 
treatment with methylprednisolone+prednisone (46.6%), 25.2% start with 
methylprednisolone+prednisone and other specific drugs and 12.1% with 
methotrexate. One year after the first treatment only 40.1% of patients continue 
receiving the same treatment, 41.4% add a specific drug, 11.7% leave therapy and 
6.8% switch to another specific drug. CONCLUSIONS: This administrative 
database is an important source of information that is able to show both 
economical indicators and the good practice of treatment. In this study, they 
point out an elevated cost per-person in drugs assumption and show very 
current tendency to switch therapy in the first year.  
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MEDICAL COSTS OF PATIENTS WITH RHEUMATOID ARTHRITIS AND ITS 
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4Istanbul University, Istanbul, Turkey, 5Ankara Numune Training and Research Hospital, 
Ankara, Turkey, 6Ege University, Izmir, Turkey, 7Cukurova University, Adana, Turkey, 8Gulhane 
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Pharmaceuticals, Istanbul, Turkey, 11STATinMED Research/The University of Michigan, Ann 
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OBJECTIVES: To identify factors associated with the cost of RA care and calculate 
risk-adjusted costs associated with RA in Turkey. We also examined the 
relationships between costs of RA treatment and global disease activity. 
METHODS: This cross-sectional study was performed in 10 university 
rheumatology centers. Eligible patients were ≥18 years of age and diagnosed with 
RA for at least 12 months according to the American College of Rheumatology 
(ACR) 1987 criteria. Generalized linear models were used to calculate risk-
adjusted direct costs. After using the Park test, the Gamma family with log link 
was chosen for the model. Age, gender, region, RA-related medication use and 
comorbidities such as diabetes, cardiovascular and respiratory disease, allergy 
and surgery were controlled in the model. Costs were adjusted by exchange rate 
of €1=2.30 Turkish Lira. RESULTS: A total of 698 patients (82% female; mean age: 
51.2±13.17 standard deviation [SD] years) were studied. Patients’ visual analog 
scale (VAS), patient’s global disease activity (GDA) and routine assessment of 
patient index data 3 (RAPID-3) scores were on average 44.15, 5.19 and 5.10 
respectively. Most patients were prescribed immunosuppressive medication and 
glucocorticoids (87.8% and 61.2%, respectively). Risk adjusted costs were 
estimated as €2,671. The most significant portion of overall expenditures was 
due to pharmaceutical costs €1987, while outpatient costs were €303, inpatient 
costs were €360 and co-payments were €21. 14% of patients experienced work 
loss due to RA. On average, annual costs due to workday loss were €480. 5.4% of 
patients also had other RA-related consultations, which were not covered by 
